HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer

NCT06849492 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Advanced Triple Negative Breast Cancer

Interventions

DRUG: Camrelizumab
DRUG: Nab-paclitaxel
DRUG: SKB264
DRUG: Lenvatinib

Sponsor

Fudan University